|Bid||5,871.00 x 0|
|Ask||5,873.00 x 0|
|Day's Range||5,795.00 - 5,879.00|
|52 Week Range||5,510.00 - 6,778.00|
|Beta (3Y Monthly)||0.31|
|PE Ratio (TTM)||29.48|
|Earnings Date||Jul 30, 2019|
|Forward Dividend & Yield||1.46 (2.50%)|
|1y Target Est||7,085.56|
Investors who take an interest in Reckitt Benckiser Group plc (LON:RB.) should definitely note that the Chief...
New York and other states have reached a $700 million settlement deal with Reckitt Benckiser over allegations that the drug distributor improperly marketed a drug to treat opioid addiction, New York Attorney General Letitia James said on Wednesday. The deal is a part of an up to $1.4 billion settlement agreed to in July to resolve U.S. state and federal claims that Reckitt Benckiser's former pharmaceuticals business Indivior, before it was spun out, carried out an illegal scheme to boost sales of opioid addiction treatment Suboxone.
Reckitt Benckiser’s stock slid on Tuesday after the consumer goods company’s new CEO hit the reset button and slashed sales expectations.
On Tuesday Reckitt Benckiser Group cut its guidance for the second time this year after weak performance from its health business, which was hurt by the tension between the U.S. and China
European stocks weakened on Tuesday, as a generally solid set of corporate earnings from companies including UBS and Saab wasn’t enough for traders to take stocks to a new high.
Mixed earnings reports kept a lid on European stocks, with London's midcap index suffering from doubts over whether British lawmakers will back the government's Brexit bill on Tuesday. The pan-European STOXX 600 finished up just 0.1%, with a weaker pound helping London's exporter-laden FTSE 100 outperform with a 0.7% gain. The FTSE 100 was also lifted by a 24% jump in food delivery firm Just Eat after Dutch internet conglomerate Prosus made an unsolicited $6.3 billion cash bid.
British household goods maker Reckitt Benckiser has cut its full-year sales forecast for the second time this year, blaming a drop in retail orders for Mucinex in the United States and a drop in demand for its Enfamil baby products in China. The Durex condom and Lysol disinfectant maker said on Tuesday it now expected full-year like for like sales growth to range from flat to up 2%, down from its previous target of 2% to 3%, which marked its second forecast cut this year. The company also said it expected to see a modest decline in adjusted operating margins for the year as it pours more money into its brands.
Reckitt Benckiser's new chief executive promised on Tuesday to step up spending on its brands and improve performance after the British household goods maker cut its full-year sales forecast for a second time. "We are not pleased with where we are and we must consistently deliver," Laxman Narasimhan, who took over from long-time CEO Rakesh Kapoor in September, said on his first call with the investment community. Narasimhan particularly lamented the performance of the firm's Health business, its largest, where a failed product launch, the nearly $17 billion acquisition of Mead Johnson, and a temporary baby milk factory shutdown in the Netherlands, have all caused significant disruption, some lasting to this day.
British household goods maker Reckitt Benckiser cut its full-year sales forecast for the second time this year, blaming a cut in retail orders of seasonal products as new Chief Executive Laxman Narsimhan took over. The Durex condom and Lysol disinfectant maker said on Tuesday it now expected full-year like-for-like sales growth to range from flat to up 2%, down from its previous target of 2% to 3%.
The big shareholder groups in Reckitt Benckiser Group plc (LON:RB.) have power over the company. Insiders often own a...
The performance of British firms who rely on the majority of their sales from European markets have plunged since the country voted to leave the EU in 2016, according to new data.
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Reckitt Benckiser Group Plc and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.